The Academy of Pharmaceutical Sciences
'Promoting the pharmaceutical sciences'


Sun Pharma, Technion to develop new class of oncology drugs.....           FDA approves Sandoz's Glatopa for multiple sclerosis treatment.....           Analyst: Vivus generic threats a positive for obesity market.....           Merck KGaA shareholders rewarded for hard work of turning company around.....           BMS' PD-1 drug Opdivo continues on stellar trajectory.....           Medimmune, Immunocore to evaluate melanoma immunotherapy combinations.....           Baxter submits NDA to Japanese authorities seeking approval for BAX 855 to treat hemophilia A.....           CiRA, Takeda to develop iPS cell applications.....           Bristol-Myers Squibb transfers Erbitux rights in North America to Lilly.....           Lexicon, Bristol-Myers select development candidate for neuropathic pain.....           Otsuka scrambles to persuade judge to block Abilify copycats.....           Pacira's Exparel marketing falls under Justice Department microscope.....           New drug partnerships in Cuba? Regeneron's chief will be on the spot.....           AbbVie moves closer to Japan's crowded hep C field with priority review nod.....           Careful, European drugmakers. Fitch says M&A may be a bit too heated.....           Sanofi expands PA vaccine facility to prepare for dengue launch.....           Bad news, Teva--Sandoz has an FDA nod for generic Copaxone. But when will it launch?.....           BMS, focused on immuno-oncology, turns Erbitux over to Eli Lilly.....           GSK closing Pittsburgh office, putting 275 jobs at risk.....           AstraZeneca's cancer drug tremelimumab obtains FDA orphan drug status.....           Abbvie's HCV treatment ombitasvir/paritaprevir/ritonavir gets priority review in Japan.....           Amgen gets FDA approval for heart failure drug Corlanor.....           Eyenovia, Senju sign license and development agreement for ophthalmic therapeutics.....           SELLAS, TrojanTec to develop new TR-1 anti-cancer antennapedia technology.....           Coherus, Baxter amend collaboration agreement for etanercept biosimilar.....           Sobi gets Swiss orphan drug designation for Elocta to treat haemophilia A.....           NewLink, Merck initiate Phase II/III Ebola trial in Sierra Leone.....           Novartis has fresh data to support newly acquired CLL drug Arzerra.....           Congress spurs feds to investigate sky-high generic drug prices.....           Pfizer's Ibrance shines in latest breast cancer study.....           Could a restructuring help protect AbbVie when revenue troubles hit?.....           Gilead's hep C drugs make it king of the hill in U.S. drug sales.....           Bayer expands copanlisib clinical development program for NHL treatment.....           FDA accepts for filing Teva and Eagle's NDA for bendamustine rapid infusion product.....           Sagent launches Vancomycin hydrochloride for injection, USP.....           Hi-Tech to buy Mexican OTC firm Advanced Pharmaceuticals and Nutritionals.....           ThromboGenics, VIB form new oncology firm to develop TB-403 for pediatric brain tumors.....           FDA grants fast track status for ARCA biopharma's Gencaro to prevent atrial fibrillation.....           Currency hurts, Olysio plummets, but J&J pharma growth carries on.....           Actavis says it'll lose $200M in Namenda sales if appeals court nixes a 'hard switch'.....           Merck's Frazier joins top-paid pharma CEOs with a $25M package.....           California health insurance exchange calls for copay caps on pricey meds.....           Record new drug sales give a mega-boost to U.S. drug spending.....           Takeda taps Lilly exec to run U.S. unit, adding a woman to its all-male exec team.....           Onglyza's label should flag heart failure risks, FDA panel says.....           Medivir, UK's Cancer Research Technology partner for new cancer drugs.....           Arrowhead gets FDA clearance to begin Phase IIb trial of ARC-520 to treat chronic HBV.....           AstraZeneca, PatientsLikeMe enter five-year research collaboration.....           Actavis, Medicines360 launch Liletta 52mg to prevent pregnancy for up to three years.....           Recro completes acquisition of Alkermes' IV/IM Meloxicam and cGMP manufacturing facility.....           Hydra Biosciences, Boehringer to discover new treatments for renal diseases and disorders.....           Eisai, Genomics to analyse large-scale genotype data to inform drug development.....           Adamas' ADS-5102 gets FDA orphan drug status for LID associated with Parkinson's disease.....           Sanofi won't discount Toujeo to Lantus.....           Zoloft lawyers accuse Pfizer of hiding birth-defect risks.....           With U.S. sales suffering, GSK plots changes to quota-free pay model.....           Medicaid drug-spending hikes rile lawmakers, but there's no end in sight.....           Actavis chairman joins Zoetis board under deal with activist investor Ackman.....           Valeant CEO's 2014 pay pales in comparison to new EVP's $50M-plus.....           Novo Nordisk opens new insulin manufacturing plant in Russia.....           Novo Nordisk opens new insulin manufacturing plant in Russia.....           Horizon gets FDA fast track status for actimmune to treat Friedreich's ataxia.....           Novo Nordisk opens new insulin manufacturing plant in Russia.....           Horizon gets FDA fast track status for actimmune to treat Friedreich's ataxia.....           Horizon gets FDA fast track status for actimmune to treat Friedreich's ataxia.....           Eisai, Genomics to analyse large-scale genotype data to inform drug development.....           Eisai, Genomics to analyse large-scale genotype data to inform drug development.....           Celgene to buy 15.3 million Mesoblast shares for $45m.....           Eisai, Genomics to analyse large-scale genotype data to inform drug development.....           Celgene to buy 15.3 million Mesoblast shares for $45m.....           Celgene to buy 15.3 million Mesoblast shares for $45m.....           Celgene to buy 15.3 million Mesoblast shares for $45m.....           Celgene to buy 15.3 million Mesoblast shares for $45m.....           Adamas gets FDA orphan drug status for ADS-5102 to treat LID associated with PD.....           Adamas gets FDA orphan drug status for ADS-5102 to treat LID associated with PD.....           Adamas gets FDA orphan drug status for ADS-5102 to treat LID associated with PD.....           Adamas gets FDA orphan drug status for ADS-5102 to treat LID associated with PD.....           Adamas gets FDA orphan drug status for ADS-5102 to treat LID associated with PD.....           US FDA modifies partial clinical hold on Tekmira's TKM-Ebola IND application.....           US FDA modifies partial clinical hold on Tekmira's TKM-Ebola IND application.....           US FDA modifies partial clinical hold on Tekmira's TKM-Ebola IND application.....           US FDA modifies partial clinical hold on Tekmira's TKM-Ebola IND application.....           US FDA modifies partial clinical hold on Tekmira's TKM-Ebola IND application.....           Reata gets FDA orphan drug status for bardoxolone methyl to treat PAH.....           Reata gets FDA orphan drug status for bardoxolone methyl to treat PAH.....           Reata gets FDA orphan drug status for bardoxolone methyl to treat PAH.....           Reata gets FDA orphan drug status for bardoxolone methyl to treat PAH.....           Reata gets FDA orphan drug status for bardoxolone methyl to treat PAH.....           Pharmacyclics reports positive longer-term results from Imbruvica Phase II trial in WM patients.....           Will Mylan's $29B bid spur other Perrigo suitors to enter the fray?.....           Study says no good has come from FDA's action on gout drug colchicine.....           Vertex's Kalydeco combo could run payers $10M-plus per life, PBM figures.....           Allergan drops Valeant-Ackman insider trading lawsuit.....           AstraZeneca's Onglyza 'mortality' risks noted by FDA reviewers.....           FDA grants priority review for Shire's lifitegrast NDA to treat dry eye disease in adults.....           Pharmacyclics reports positive longer-term results from Phase II trial of Imbruvica in WM patients.....           FDA grants fast track status for Exelixis? carcinoma drug cabozantinib.....           Cipla EU agrees to acquire Brazilian drug distributor Duomed.....           Acura to develop hydrocodone/APAP tablets using Limitx technology.....           MedImmune gets FDA fast track status for MEDI8897 to prevent LRTI caused by RSV in infants.....           Eisai to cut workforce by 25% in US.....           RSS NEWSFEED....
Welcome to
The Academy of
Pharmaceutical Sciences
 
The Academy of Pharmaceutical Sciences (APS) is the UK-based professional membership body for Pharmaceutical Scientists.

We represent individuals and organisations from around the globe, throughout their development, in the delivery of excellence in the Pharmaceutical Science sector.
 
 
Recent meetings

APS Freeze drying and alternative drying technologies for parenterals

28 January 2015 - Loughborough

Freeze drying - is there an alternative process technology to consider for your biopharmaceuticals?

A very successful one day meeting was held to look at the latest challenges and opportunities in the preservation of biopharmaceuticals. The meeting explored new developments in the established technology of freeze drying and discussed possible alternatives of spray drying, protein crystallisation and supercritical fluid drying of biopharmaceuticals.

Read more...

Latest News
Conference Awards: 5th APS International PharmSci Conference
TUESDAY, 7 APRIL 2015
5th APS International PharmSci Conference: Nottingham 2015. . Conference Awards:. APS Award Lecture sponsored by AstraZeneca; Call for Nominations. The APS is pleased to announce our Call for Nominations for this years APS Award Lecture sponsored by AstraZeneca, to be delivered at APS PharmSci 2015 (September 7th- 9th) at the East Midlands Conference Centre, Nottingham.. The award will entail the following for the recipient:. To be presented at APS PharmSci 2015 with complimentary registration for the event on the day.. To deliver a 45 minute lecture within a conference plenary session. Presentation of a cheque to be donated to a charity of your choice. To be recognized as an award recipient on the APS website. Nominations Nomination should consist of a brief C.V. and a 1 page summary of contribution in fields of:. Scientific contribution: Work should be outstanding and ambassadorial in their area with an international reputation Broad scientific awareness Nominations must be made by member of the Academy. Selection Process The recipient of the award will be appointed by a Selection Committee comprising of:. Representatives of the Academy Board Representatives of the APS PharmSci 2015 Organizing Committee . GSK Emerging Scientist Award 2015; Call for Nominations. GlaxoSmithKline and the Academy of Pharmaceutical Sciences present the GSK Emerging Scientist Award and invite post-graduate and post-doctoral researchers to submit an application.. Prize The winner will receive a Commemorative Award, £1,000 in prize money and an invitation to present the GSK Emerging Scientist Award Lecture on their work at APS PharmSci 2015.. Entry Criteria Entrants are welcome from researchers from across the globe in academia, industry, public service or other scientific establishments. The individual applicant should have demonstrated, through published work, a significant innovation which has the potential for application within the pharmaceutical industry.. Applicants must be within 10 years of commencing their first research position on the closing date to be eligible. Time spent in undergraduate education is excluded. Clarification on eligibility can be sought by submitting a copy of your CV to the APS at info@apsgb.org.. Submission Criteria Applicants are requested to submit their CV and a synopsis of their research of not more than 1000 words, focussing on its importance to the pharmaceutical industry. Diagrams and images will account for 50 words. Any references used should be cited fully using the Harvard system.. Entries should be submitted via email to Alan Ramsay at info@apsgb.org including ‘Emerging Scientist Award 2015’ in the subject field. Your email application must include your full name and postal address, a contact telephone number, your email, and your institution or organisation’s name. Entries will be judged by an APS panel.. . Timings Nominations for both awards must be received by Friday 5th June 2015 and should be sent to:. Email: info@apsgb.org. Or by post to:. The Organising Committee APS PharmSci 2014 Academy of Pharmaceutical Sciences Unit Q Troon Way Business Centre Humberston Lane Leicester LE4 9HA. . Tel: 0116 274 7351. Fax: 0116 274 7365. . APS Emerging Scientist Bright Ideas Award 2015; Call for Nominations. In conjunction with this year’s conference (7th - 9th September, East Midland’s Conference Centre, Nottingham) we are pleased to announce the APS Emerging Scientists’ Bright Idea Award.. Applications are invited from students, undergraduates, recent graduates and recent post-docs to submit an innovative Bright Idea related to the Pharmaceutical Sciences with the chance for an Award of £500 as a contribution to turn the best idea into reality.. In addition to the Award the winner will be provided with the support of an experienced APS Board member to help them with their idea.. Applicants will be invited to present no-more than 2 slides on their idea at a session of the conference on Monday 7th September. There will be a vote on the ideas presented and the winner will be announced later in the day.. In the first instance you are invited to submit no more than 2 paragraphs detailing your idea and how you would spend £500 to progress it. . Last year’s entries included:. Patch with feedback to control drug delivery. Means of purifying API from trace impurities. Improving the understanding of roller compaction. Pre-filled syringes to dose paediatrics. 3D printing of drug doses -. Entries clearly marked as ‘APS Bright Idea Competition’ should be Emailed to Info@APSGB.org to arrive no later than Friday 31st July 2015..
The academy of Pharmaceutical Sciences announces nomination for their awards of Fellowship and Eminent Fellowship of the Academy for 2015
THURSDAY, 2 APRIL 2015
The Academy of Pharmaceutical Sciences is pleased to announce nominations for two highly recognised and prestigious awards within pharmaceutical science for their members: Fellowship and Eminent Fellowship of the Academy. Fellowship of the Academy (self-nomination). The fellowship of the Academy is a science driven award and is self-nominated by members of the APS. Individuals nominating can come from all sectors where pharmaceutical scientists work, which is reflected in the criteria for eligibility. . Eligibility requirements. The nominated person must:. Have a minimum of 8 post training years in the pharmaceutical sciences. Have a minimum of 15 peer reviewed publications and /orpatents, with at least 2/3 as first or corresponding/senior author. Or have contributed substantially to the development of a medicinal product(s) , diagnostic or device. Or have contributed substantially to the development of novel technologies. Or have contributed substantially to pharmaceutical science education/training as evidenced by peer recognition- invited lectures, conference leadership, etc. and involvement in mentorship. Application process. Nominations are required to submit a CV and a one page summary detailing their contributions made using the above guidance.. Nominations must be sent to info@apsgb.org and received by the April 30th 2015. These will then be reviewed by the APS Board and applicants will be notified of the result by June 2015.. . Eminent Fellowship of the Academy (nominated by an APS member). This is an award recognising science and experience at international level with emphasis on advocacy and leadership and nominations of deserving individuals are made by APS members with two letters of support. Nomination can be from all sectors where pharmaceutical scientists work, which is reflected in the criteria for eligibility. . Eligibility requirements. The nominated person must:. Have a minimum of 10 years post qualification of involvement in the pharmaceutical sciences. Have made a significant contribution to multiple publications and /or patents. Be in a clear leadership role. Be recognised internationally for their achievements . Application process. The Nomination will be from an APS member with 2 letters of support (also from APS members). Nominations will require a two page CV and a one page career summary detailing the contributions made highlighting the criteria above. The individual being nominated would typically not be aware of their nomination.. Nominations must be sent to info@apsgb.org and received by April 30th 2015. The APS board will appoint a review panel (3) composed of Board and Advisory Board members and individuals making the nomination will be notified of the result by June 2015 for subsequent onward notification to the individual being nominated.. Past members who have won the Eminent Fellowship of the Academy can be seen on the APS website http://www.apsgb.co.uk/dev/awards.asp. Please contact info@apsgb.org or telephone 0116 274 7531.
5th International APS PharmSci Conference 2015
TUESDAY, 31 MARCH 2015
7th - 9th September 2015, East Midlands Conference Centre, Nottingham. ONLINE REGISTRATION NOW OPEN The Academy of Pharmaceutical Scientist is pleased to announce that registration for the 5th International APS PharmSci Conference 2015 is now open! . The APS PharmSci 2015 Conference will showcase the best of pharmaceutical science from the UK and around the world bringing together academic and industrial institutions, providing state of the art technologies and a platform for the development of new pharmaceutical talent. The intention is to work with related partner organisations such as, JPAG, UK&ICRS, and the RPS together with the Academy's Focus Groups to deliver a high quality science programme.. For more information visit: www.ukpharmsci.org. . CALL FOR PAPERS The abstract submission process is now open. For more information on submitting an abstract, please visit us online here: http://www.ukpharmsci.org/abstracts/default.asp. The deadline for receipt of submissions is Friday, 1st May 2015. . . EXHIBITION OPPORTUNITIES Exhibition space for one of the country's largest gatherings of industrial scientists, academics, management and technicians involved in the "Science of Medicines" can now be reserved online using our interactive floorplan. . If you are interested in exhibiting please visit http://www.ukpharmsci.org/exhibition/ or contact Alan Ramsay on T: 0116 274 7351 for details or to reserve your space.. PLEASE NOTE EXHIBITION SPACES ARE LIMITED, SO DON'T DELAY AND BOOK YOUR STAND TODAY.. . SPONSORSHIP OPPORTUNITIES PharmSci 2015 provides your organisation with an ideal opportunity to increase it profile through a wide range of sponsorship opportunities. . For further details please contact Alan Ramsay on T: 0116 274 7351. .
APS Parkinson's Disease: From Patient to Product
TUESDAY, 24 MARCH 2015
Venue: GSK, Ware Tuesday 19th May 2015. Parkinson’s Disease affects one in 500 people, with an estimated prevalence of 127,000 people in the UK with the condition. The use of medicines is a mainstay in treatment and can lead to an improvement in symptoms and movement. However, as the disease progresses, this presents challenges to patients, carers and prescribers in terms of what to prescribe and how it is administered. These challenges require science and clinical practice to come together to develop solutions to optimise treatment management for patients. This one-day meeting organised by the Age-Related Medicines Focus Group, will showcase the latest research in science and clinical practice pertaining to Parkinson’s Disease, present the perspectives of patients, and highlight regulatory perspectives in drug development.. The APS is grateful to GSK for their contribution to this event. As part of their 300th year celebrations, GSK are hosting a number of scientific events including this one.. For more details on the programme, fee's and to register, please visit us online here:. http://www.apsgb.co.uk/EVENTS/20150519/Default.asp. .
 
Follow us
 
Upcoming Events
APS Board Meeting
28 - 29 April 2015
APS Parkinson's Disease: From Patient to Product
19 May 2015
APS Inhaled Product Development Workshop
11 - 12 June 2015
APS 5th International PharmSci Conference 2015
7 - 9 September 2015
APS Joint Meeting with BSNM
10 September 2015
Job Vacancies
View all Vacancies
Advertise your job vacancies
Sponsored By
Join Us

Join the academy and get discounts on events, post-nominals, latest news and more.

 

The Academy of Pharmaceutical Sciences
Unit Q, Troon Way Business Centre
Humberstone Lane, Leicester, LE4 9HA
Tel: 0116 274 7351
Fax: 0116 274 7365
Email: info@apsgb.org

Terms of use:
The material included on this site is provided for information purposes only, and we make no representations or warranties as to its accuracy. Before relying on this material, you should take care to verify its accuracy, taking professional advice as appropriate.